Sign up to receive Trinity’s 3rd Annual State of Global Market Access
Life sciences leaders who want a deeper view into global market access trends can sign up to receive Trinity’s annual State of Global Market Access white paper once it is released.
The paper provides a cross-region view of how:
- US MFN policy and new CMS reference pricing models are reshaping federal pricing and rebates
- The rapid expansion of direct-to-consumer channels is changing patient access and pricing signals
- China’s multi-tiered reimbursement system is emerging, with NRDL, Category C, and early access programs
- Growing HTA rigor and localization in LatAm and MENA are raising evidence demands and influencing price setting
- Early regulatory–HTA convergence in Europe is tightening links between trial design, approval, and access decisions
It is designed to help teams anticipate what lies ahead in 2026 and beyond with regional insights, payer perspectives, real-world examples, and Trinity’s strategic recommendations.
To receive a copy as soon as it becomes available, please complete the form below.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
In case you missed it – on-demand webinar:
Around the World in Market Access: 2026 Global Trends Life Sciences Leaders Need to Watch
Based on Trinity’s 3rd Annual State of Global Market Access white paper, this webinar will take you “around the world” with focused updates on the US, Europe, Asia Pacific, and Latin America. Trinity experts will connect policy and access developments to practical implications for launch sequencing, evidence planning, pricing strategies, and in‑line optimization so teams can pressure‑test current plans and prepare for what’s next.